Aurobindo Pharma gets warning letter from USFDA for Andhra unit

The company has received a warning letter from the United States Food and Drug Administration (USFDA) relating to our unit XI, active pharmaceutical ingredient (API) manufacturing facility situated at Srikakulam District, Andhra Pradesh. This action follows the earlier inspection of the site by the USFDA in February 2019, Aurobindo Pharma said in BSE filing.

from Moneycontrol Business News http://bit.ly/2IvB5SB